GlassScriptPhysician profile
Talin Amadian
NPI 1043796147
$18,127.46
in general payments reported to CMS, 2019-2025
22 companies · $547 in 2025
The $547 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $1,362 · 2021: $2,289 · 2022: $1,395 · 2023: $7,084 · 2024: $4,547 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,908 · Food and Beverage: $3,712 · Travel and Lodging: $2,171 · Entertainment: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,908.01 |
| Food and Beverage | $3,712.29 |
| Travel and Lodging | $2,170.84 |
| Entertainment | $386.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $8,920.30 | 2020-2024 | Tearcare System |
| Coopervision INC. | $3,774.72 | 2021-2025 | Cvi Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $1,776.97 | 2019-2025 | Precision 1, Total30, Clareon |
| Lumenis Be INC | $1,000.00 | 2023 | Optilight |
| Optos, INC. | $671.54 | 2020-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $531.65 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $327.30 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $209.21 | 2019-2023 | Acuvue |
| Lombart Brothers, INC. | $144.36 | 2025 | Opd-III |
| Topcon Healthcare, INC. | $142.70 | 2023 | |
| Dompe US, INC. | $137.11 | 2022-2025 | Oxervate |
| Maculogix, INC. | $118.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.35 | 2019-2023 | |
| Genentech USA, INC. | $59.07 | 2019 | |
| Abbvie INC. | $58.87 | 2023 | Vuity, Lumigan, Alphagan P |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $39.02 | 2025 | Triesence |
| Bausch & Lomb Americas INC. | $37.65 | 2022-2024 | Xiidra, Miebo |
| Biotissue Holdings INC. | $28.83 | 2023 | |
| Allergan, INC. | $26.76 | 2021 | |
| Shire North American Group INC | $25.84 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $17.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talin Amadian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.